Introdução: A maioria dos pacientes acometidos pela neoplasia que envolve a confluência biliopancreática é diagnosticada em fase avançada. A Colangiopancreatografia Retrógrada Endoscópica (CPRE) é o método de escolha para a drenagem da via biliar obstruída. Todavia, existe um índice de insucesso em torno de 10%. Nesses casos, técnicas alternativas serão aplicadas, como drenagem percutânea trans-hepática e drenagens cirúrgicas. Objetivo: Avaliar o sucesso técnico, clínico, qualidade de vida e sobrevida da drenagem biliar pela cirurgia convencional e técnica endoscópica ecoguiada em pacientes portadores de neoplasia maligna da confluência biliopancreática. Método: No período de abril de 2010 a setembro de 2013, foram estudados 32 pacientes portadores de neoplasia maligna da confluência biliopancreática. Todos os que foram incluídos nesse estudo apresentaram falha na drenagem biliar por CPRE. Três deles foram excluídos por insucesso técnico (falha na confecção da anastomose hepaticojejunal e da formação da fístula coledocoduodenal ecoguiada). O Grupo I foi formado por 15 pacientes submetidos à Hepaticojejunostomia (HJT) em \"Y\" de Roux e derivação gastrojejunal. O Grupo II foi formado por 14 pacientes submetidos à coledocoduodenostomia ecoguiada (CDT). O sucesso clínico foi avaliado pela queda da bilirrubina sérica total em mais de 50% nos sete primeiros dias após o procedimento. A qualidade de vida foi avaliada pelo questionário SF-36 e a sobrevida pela curva de Kaplan-Meier. Resultados: O sucesso técnico foi de 93,75% (15/16) no Grupo I e de 87,5% (14/16) no Grupo II (p = 0,598). O sucesso clínico ocorreu em 14 (93,33%) pacientes pertencentes ao Grupo I e em 10 (71,43%) do Grupo II. Não houve diferença estatisticamente significativa (p = 0,169). O comportamento médio dos escores de qualidade de vida foi estatisticamente igual entre as técnicas ao longo do seguimento (p > 0,05 Técnica * Momento). Houve alteração média estatisticamente significativa ao longo do seguimento nos escores de capacidade funcional, saúde física, dor, aspectos sociais, aspectos emocionais e saúde mental em ambas as técnicas (p < 0,05). O escore de saúde mental foi, em média, estatisticamente maior nos do Grupo II (CDT) em todos os momentos (p = 0,035). O tempo médio de sobrevida daqueles pertencentes ao Grupo I foi de 82,27 dias e os do Grupo II, de 82,36 dias. Sessenta por cento dos pertencentes ao Grupo I faleceram até 90 dias após o procedimento cirúrgico. Por outro lado, 42,9% dos submetidos à CDT faleceram no mesmo período. Não houve diferença estatisticamente significativa no tempo de sobrevida entre os Grupos (p = 0,389). Conclusão: Os dados relacionados aos sucessos técnico, clínico, qualidade de vida e sobrevida foram semelhantes em ambos os grupos, não se verificando diferença estatisticamente significativa / Introduction: Most patients with neoplasm in the biliopancreatic junction are diagnosed at an advanced stage. Endoscopic retrograde cholangiopancreatography (ERCP) is the method of choice for drainage of obstructed biliary tract. However, there is a failure rate of about 10%. In such cases, alternative techniques, such as, percutaneous transhepatic drainage and surgical drainage are applied. Aim: To evaluate the technical and clinical success, quality of life and patient survival of biliary drainage by conventional surgery and endosonography-guided technique in patients with malignant neoplasm of the biliopancreatic junction. Methodology: From April 2010 to September 2013, 32 patients with malignant neoplasm of the biliopancreatic junction were studied. All patients included in this study had failed biliary drainage by ERCP. Three patients were excluded due to technical failure (failure in the construction of hepatico-jejuno anastomosis and formation of endosonography-guided choledochoduodenal fistula). Group I comprised of 15 patients who underwent Roux-en-Y hepaticojejunostomy (HJT) and gastrojejunal bypass. Group II consisted of 14 patients who underwent endosonography-guided choledochoduodenostomy (CDT). Clinical success was assessed by the decrease of more than 50% in total serum bilirubin in the first seven days after the procedure. Quality of life was assessed by SF-36 questionnaire and survival by Kaplan-Meier curve. Results: Technical success rate was 93.75% (15/16) in group I and 87.5% (14/16) in group II (p = 0.598). Clinical success occurred in 14 (93.33%) patients in group I and 10 (71.43%) patients in group II. There was no significant statistically difference (p = 0.169). The average quality of life score were statistically equal between the techniques during follow-up (p > 0.05 * Technical Moment). There were statistically significant mean changes during follow-up of functional capacity score, physical health, pain, social functioning, emotional and mental health aspects in both techniques (p < 0.05). The mental health score was, on average, statistically higher in group II (CDT) at all times (p = 0.035). The median survival time of patients in group I was 82.27 days and Group II patients was 82.36 days. Sixty percent of patients in group I died within 90 days after the surgical procedure. On the other hand, 42.9% of the patients who underwent CDT died in the same period. There was no statistically significant difference in survival time between the groups (p = 0.389). Conclusion: Data relating to technical and clinical success, quality of life and survival were similar in both groups and there were no statistically significant differences

Objectif : Déterminer la prévalence de la Sclérose systémique (SSc) chez les patients atteints de cirrhose biliaire primitive (CBP) et décrire les caractéristiques cliniques, pronostiques, immunologiques et capillaroscopiques chez les patients avec et sans SSc. Méthode : Étude descriptive de 100 patients avec CBP naïfs de SSc référés par les gastroentérologues. Un examen physique ainsi qu’un prélèvement sanguin et une capillaroscopie ont été réalisés. Résultats : Parmi les 22 patients diagnostiqués avec SSc, 13 n’avaient pas d’atteinte cutanée. Trente-neuf patients présentaient un phénomène de Raynaud. Dix-neuf étaient anticentromères (ACAs) positifs dont 18 avaient une SSc. Le groupe de CBP avec SSc avait un score Mayo meilleur et une atteinte histologique moins sévère. Une capillaroscopie anormale était retrouvée chez 29/100 patients. Les patients sans ACAs avaient une hypertension portale légèrement plus fréquente 14/81 (17,28%, p= 0,876) et une atteinte histologique hépatique plus sévère (89,5%, p=0,125). Le score Mayo était globalement meilleur dans le groupe des ACAs positifs. La sensibilité et la spécificité du test immunologique sont 95,45% et 93,59% respectivement. La capillaroscopie a une sensibilité de 78% et une spécificité de 94% pour le diagnostic de la SSc dans la population de CBP.   Conclusion : La SSc est fréquente dans la CBP, d’où l’intérêt de rechercher systématiquement les signes cliniques subtiles de la SSc, notamment le phénomène de Raynaud, et de demander une sérologie spécifique et une capillaroscopie pour identifier une SSc débutante. / Objective : To determine the prevalence of systemic scleroderma (SSc) in patients with primary biliary cirrhosis (PBC) and to describe the clinical, prognostic, immunologic and nailfold capillaropscopy characteristics in patients with and without SSc. Study design : In this descriptive cohort study, 100 patients with PBC who were unknown for any connective tissue disease, in particular for SSc, were referred by their gastroenterologist. Physical examination with collection of serum samples and nailfold capillaroscopy examination were performed. Results : Twenty-two patients had been diagnosed with SSc of which 13 had no cutaneous manifestations of scleroderma. Thirty-Nine patients had Raynaud’s phenomenon. Of the 19 patients with anticentromères antibodies (ACAs), 18 had SSc. Patients with PBC and SSc had a better Mayo score and less severe liver damage. Twenty-nine patients had abnormal nailfold capillaroscopy. More frequent portal hypertension 14/81 (17,28%, p= 0,876) and severe liver tissue damage (89.5%, p=0.125) seen in patients with positive ACAs. Mayo score was better in patients with positives ACAs. The sensitivity and specificity of the immunologic tests were 95,45% and 93,59% respectively. The sensitivity of nailfold capillaroscopy was 78% and specificity was 94% for the diagnosis of SSc in patients with PBC.   Conclusion : SSc is more prevalent in PBC. This study highlights the importance of screening for subtle clinical signs of SSc in patients with PBC, in particular Raynaud’s phenomenon, hence requiring immunologic tests and nailfold capillaroscopy to diagnose scleroderma at earlier stages.

Este trabalho consiste na caracterização química e termoanalítica da composição química de cálculos biliares e bile humana, coletados da vesícula biliar de pacientes que foram submetidos à colecistectomia no Hospital Universitário da Universidade de São Paulo. As metodologias utilizadas para amostragem, caracterização química e termoanalítica foram previamente otimizadas por um estudo preliminar, trabalhando-se com um total de 38 amostras de cálculos biliares e bile da vesícula biliar humana. A técnica de análise elementar para a determinação dos teores de carbono, hidrogênio e nitrogênio foi usada para a caracterização química junto com a espectroscopia de absorção na região do infravermelho e difração de raios X. Esses resultados foram complementados por dados obtidos pelas técnicas termoanalíticas TG/DTG e DSC. O estudo do comportamento térmico foi realizado empregando as técnicas TG/DTG em atmosfera dinâmica de ar e razão de aquecimento de 10 ºC min-1. No caso da amostra de cálculo biliar SF15, considerada atípica por apresentar um teor de 81% de CaCO3 na sua composição química, utilizou-se atmosfera mista de ar+CO2. Em todos os ensaios foram empregados. Os eventos térmicos (físicos e químicos) foram evidenciados pelas curvas DSC, por picos no sentido endotérmicos e exotérmicos. A comparação dos perfis das curvas TG/DTG e os resultados de perdas de massa evidenciaram junto com os teores de CHN obtidos por análise elementar, possibilitaram classificar os cálculos biliares em oito grupos distintos (A, B, C, D, E, F, G e H). As curvas DSC, os espectros de infravermelho e os difratogramas de raios X, confirmaram a distinção da composição química desses grupos. Deste modo, foi possível a elaboração de uma nova classificação para os cálculos biliares da vesícula biliar humana baseado na sua composição química. / This work consists of the chemical characterization and thermoanalytical of the chemical composition of gallstones and human bile, collected of the gallbladder of patients that were submitted to cholecystectomy at University Hospital of São Paulo University. The methodologies used to sampling, chemical characterization and thermoanalytical were previously optimized for a preliminary study, working with a total of 38 gallstones and human bile samples. For chemical characterization elementary analysis techniques, to carbon, hydrogen and nitrogen determination, infrared spectroscopy and X-rays diffraction were used, these results complemented the obtained thermoanalytical data for TG/DTG and DSC techniques. The gallstones and bile samples thermal behavior study was accomplished using the techniques TG/DTG in dynamic air atmosphere. In the case gallstone SF15 sample, considered like abnormal due to its content of 81% of CaCO3 in its chemical composition. For this one, a mixture air + CO2 was used. In all experiments were used heating rate of 10 °C min-1. The thermal events (physical and chemical) were evidenced by the DSC curves, with endothermic and exothermic peaks. By means of the comparison TG/DTG curves profiles, the results of mass losses for them evidenced, with CHN\'s contents obtained for elementary analysis, they can classify the gallstones in eight distinct groups (A, B, C, D, E, F, G and H). The DSC curves, infrared spectra and X-rays diffraction, they confirmed the chemical composition distinction of these groups. Thus, it was possible the elaboration of a new classification for the gallstones formatted in the human gallbladder based in your chemical composition.

A atresia das vias biliares é afecção hepática da infância. A etiologia é desconhecida, e o diagnóstico baseia-se na biópsia hepática, cujo achado é a proliferação ductular. A ligadura do ducto biliar comum em ratos é modelo utilizado para estudo das doenças colestáticas. A proposta do trabalho foi estudar, em modelo experimental de obstrução biliar, as alterações histológicas hepáticas em ratos jovens e compará-las com o animal adulto. Avaliou-se a semiquantificação da proliferação ductular e inflamação pelo HE; quantificação da fibrose portal e periportal pelo picrosírius; semiquantificação da expressão de desmina e a-actina de músculo liso pelas células estreladas e miofibroblastos. Apesar das respostas de proliferação ductular e inflamação mais lentas no rato jovem, a fibrose e a expressão de desmina foram mais intensas neste grupo / Biliary atresia is an hepatic disease of infancy. Etiology is unknown, and diagnosis is made by liver biopsy, with ductular proliferation being the main histological feature. Bile duct ligation in rats is an useful experimental model of biliary obstruction. The aim of this study of extra-hepatic cholestasis was analyse hepatic histological alterations in young rats compared to adult animals. The responses were studied by semiquantification of ductular proliferation and inflammatory infiltrated by HE stain; quantification of portal and periportal fibrosis with the sirius-red stain; semiquantification of the expression of desmin and a-smooth muscle actin by the hepatic stellated cells and myofibroblasts. In young animals, despite the very slow response of ductular proliferation and inflammation observed with HE, there were significantly more fibrosis and expression of desmin than in adult group

In vivo studies of hepatobiliary disposition are challenging. The hepatobiliary system is complex, as its physiological localization, complex cellular structure with numerous transporters and enzymes, and the interindividual variability in protein expression and biliary flow will all affect the in vivo disposition of a drug under investigation. The research included in this thesis has focused on the involvement of hepatic transport proteins in the hepatobiliary disposition of rosuvastatin. The impact that several transport inhibitors had on the pharmacokinetics of rosuvastatin was investigated in healthy volunteers and in pigs. The effects were considerable, following inhibition of sinusoidal transport proteins by cyclosporine and rifampicin. These inhibitors significantly reduced the hepatic extraction of rosuvastatin by 50 and 35%, respectively, and the plasma exposure increased by factors of 9.1 and 6.3, respectively. Drug-drug interactions (DDI) resulting in markedly higher plasma exposures are important from a drug safety perspective as increased extrahepatic exposure of statins is associated with an increased risk of severe side-effects, such as myopathy which in rare cases could develop into rhabdomyolysis. The DDI caused by cyclosporine and rifampicin can probably be attributed to inhibition of hepatic uptake transporters. In contrast, inhibition of canalicular transporters by imatinib did not significantly affect the pharmacokinetics of rosuvastatin, which suggests that the intracellular concentration of the inhibitor in the hepatocyte was insufficient to affect the transport of rosuvastatin, or that imatinib is not a sufficiently potent inhibitor in vivo. Furthermore, gemfibrozil administered as a single dose into the jejunum in healthy volunteers and pigs did not affect the plasma or biliary pharmacokinetics of rosuvastatin. The previously reported DDI in humans upon repeated dosing with gemfibrozil might be explained by the accumulation of metabolites able to affect the disposition of rosuvastatin. The investigations presented in this thesis conclude that transport proteins are of considerable importance for the hepatobiliary disposition of rosuvastatin in vivo. The Loc-I-Gut catheter can be applied for the investigation of biliary accumulation and to determine bile specific metabolites, however it has limitations when conducting quantitative measurements. In the porcine model, hepatic bile can be collected for up to six hours and enables the determination of the hepatic extraction in vivo.

Introduction: Intraperitoneal tumor seeding is a common form of recurrence after surgery for GI tumours. Early diagnosis and treatment may influence the course of disease. Hypothesis and objectives of the work The finding of free tumor cells and / or elevation of tumor markers in peritoneal fluid predicts intraperitoneal tumor recurrence. The results of these tests can be used to indicate HIPEC. Aim of this work is to determine the sensitivity and specificity of cytology and tumor markers levels and importance of these tests for early diagnosis and prognosis of recurrence. Another objective was to confirm the applicability of RT PCR for identification of free tumor cells. Patients and methods . Materials are sourced both during initial surgery (220 patients) and by the dispensary controls (25 patients). The peritoneal fluid was examined cytologically and biochemically too. 50 samples was exemined by RT PCR. Results Elevation of tumor markers or finding of free intraperitoneal tumor cells predicts recurrence. The prognosis of these patients corresponds to stage IV TNM classification, regardless of other parameters TNM. Low sensitivity of these tests (34% for cytology, 53% for tumor markers) does not allow its use as an indicator of HIPEC. Due to degradation of RNA we did not confirm the value of RT...

A atresia das vias biliares é afecção hepática da infância. A etiologia é desconhecida, e o diagnóstico baseia-se na biópsia hepática, cujo achado é a proliferação ductular. A ligadura do ducto biliar comum em ratos é modelo utilizado para estudo das doenças colestáticas. A proposta do trabalho foi estudar, em modelo experimental de obstrução biliar, as alterações histológicas hepáticas em ratos jovens e compará-las com o animal adulto. Avaliou-se a semiquantificação da proliferação ductular e inflamação pelo HE; quantificação da fibrose portal e periportal pelo picrosírius; semiquantificação da expressão de desmina e a-actina de músculo liso pelas células estreladas e miofibroblastos. Apesar das respostas de proliferação ductular e inflamação mais lentas no rato jovem, a fibrose e a expressão de desmina foram mais intensas neste grupo / Biliary atresia is an hepatic disease of infancy. Etiology is unknown, and diagnosis is made by liver biopsy, with ductular proliferation being the main histological feature. Bile duct ligation in rats is an useful experimental model of biliary obstruction. The aim of this study of extra-hepatic cholestasis was analyse hepatic histological alterations in young rats compared to adult animals. The responses were studied by semiquantification of ductular proliferation and inflammatory infiltrated by HE stain; quantification of portal and periportal fibrosis with the sirius-red stain; semiquantification of the expression of desmin and a-smooth muscle actin by the hepatic stellated cells and myofibroblasts. In young animals, despite the very slow response of ductular proliferation and inflammation observed with HE, there were significantly more fibrosis and expression of desmin than in adult group

L’insuffisance rénale chronique (IRC) affecte 13 % de la population américaine et son incidence ne cesse d’augmenter. Malgré un ajustement des doses de médicaments administrés en fonction du taux de filtration glomérulaire du patient urémique, près de 40 % des patients reçoivent une dose trop élevée en raison de modifications de l’élimination extrarénale des médicaments chez ces patients. Il est connu que l’IRC affecte l’élimination métabolique des médicaments par les cytochromes P450 et les enzymes de biotransformation de phase II. Nous avons aussi démontré, chez le rat, que l’IRC affecte l’expression et l’activité de transporteurs de médicaments intestinaux entraînant une augmentation de la biodisponibilité de certains médicaments. On retrouve des transporteurs de médicaments dans de nombreux organes comme le foie, les reins et la barrière hématoencéphalique (BHE) où ils jouent des rôles importants dans les éliminations biliaire et rénale et la pénétration des médicaments au cerveau. Le but de ce travail était de mesurer, chez des rats néphrectomisés, les impacts de l’IRC sur l’expression protéique et génique et l’activité des transporteurs de médicaments hépatiques, rénaux et cérébraux. Les transporteurs étudiés sont de la famille des transporteurs ABC (P-glycoprotéine, multidrug-resistance related protein, breast cancer resistance protein) ou des solute carriers (organic anion transporter, organic anion transporting protein). Aussi, une étude réalisée chez l’humain visait à évaluer la pharmacocinétique de deux médicaments : la fexofénadine, un médicament majoritairement transporté, et le midazolam, un substrat du cytochrome P450 3A4, chez des sujets dialysés. Nos résultats montrent que, chez le rat, l’IRC entraîne des modulations de l’expression des transporteurs d’influx et d’efflux hépatiques pouvant entraîner des diminutions du métabolisme hépatique et de l’excrétion biliaire des médicaments. Dans le rein, nous avons démontré des modulations de l’expression des transporteurs de médicaments. Nous avons aussi démontré que l’IRC diminue l’élimination urinaire de la rhodamine 123 et favorise l’accumulation intrarénale de médicaments transportés comme la benzylpénicilline et la digoxine. À la BHE, nous avons démontré des diminutions de l’expression des transporteurs de médicaments. Toutefois, nous n’avons pas observé d’accumulation intracérébrale de trois substrats utilisés (digoxine, doxorubicine et vérapamil) et même une diminution de l’accumulation intracérébrale de la benzylpénicilline. Il semble donc que, malgré les modulations de l’expression des différents transporteurs de médicaments, l’intégrité et la fonction de la BHE soient conservées en IRC. Chez l’humain, nous avons démontré une augmentation de la surface sous la courbe de la fexofénadine chez les sujets dialysés, comparativement aux témoins, suggérant une altération des mécanismes de transport des médicaments chez ces patients. Nous n’avons, toutefois, pas observé de modification de la pharmacocinétique du midazolam chez les patients dialysés, suggérant une activité métabolique normale chez ces patients. Un ou des facteurs s’accumulant dans le sérum des sujets urémiques semblent responsables des modulations de l’expression et de l’activité des transporteurs de médicaments observées chez le rat et l’humain. Ces travaux mettent en évidence une nouvelle problématique chez les sujets urémiques. Nous devons maintenant identifier les mécanismes impliqués afin d’éventuellement développer des stratégies pour prévenir la toxicité et la morbidité chez ces patients. / Chronic renal failure (CRF) affects 13% of the American population and its incidence is rising. Despite dose adjustment of drugs administered to CRF patients according to their glomerular filtration rate, nearly 40% of patients receive up to 6,45-times the recommended dose due to modifications in the extra-renal elimination of drugs. It is known that CRF affects the metabolic elimination of drugs via cytochrome P450s and Phase II biotransformation enzymes. Also, we showed modulations in the expression and activity of intestinal drug transporters in CRF rats that could lead to increases in the bioavailability of drugs. Drug transporters are expressed in various organs including the liver, the kidneys and the blood-brain barrier (BBB) where they play important roles in the biliary and renal elimination, and the brain penetration of drugs. The objective of this work was to measure, using a rat model of CRF, the impacts of CRF on the protein and mRNA expression and the activity of liver, kidney and brain drug transporters. We studied ABC transporters (P-glycoprotein, multidrug-resistance related protein, breast cancer resistance protein) and solute carriers (organic anion transporters, organic anion transporting proteins). Also, a study conducted in human aimed to evaluate the pharmacokinetics of two drugs: fexofenadine, a transported drug, and midazolam, a substrate of cytochrome P450 3A4, in dialyzed patients. In rats, our results show modulations in the expression and activity of hepatic influx and efflux drug transporters that could lead to decreases in the hepatic metabolism and biliary excretion of drugs. In the kidney, we demonstrated modulations in the expression of drug transporters in CRF rats. We also demonstrated that CRF causes a reduction of the urinary elimination of rhodamine 123, a P-glycoprotein substrate, and the intra-renal accumulation of at least two transported drugs: benzylpenicillin and digoxin. Finally, we demonstrated decreases in the expression of influx and efflux drug transporters at the BBB of CRF rats. However, these decreases did not correlate with in vivo changes since BBB permeability of benzylpenicillin was decreased in CRF rats while digoxin, doxorubicin and verapamil permeabilities were unchanged. It thus appears that, even with decreased drug transporters, BBB integrity and function is conserved in CRF. In human, we showed an increase in the area under the curve of fexofenadine in dialyzed subjects compared to healthy controls, suggesting alterations of drug transport mechanisms in these patients. However, we observed no modifications in the pharmacokinetics of midazolam in dialyzed patients, suggesting a normal metabolic activity in these patients. Results from in vitro studies suggest that one or many uremic factors accumulating in the serum of uremic rats and patients are responsible for the observed modulations in drug transporter expression and activity observed in rat and human. This work demonstrates the impacts of CRF on the expression and activity of drug transporters and how they could affect drug pharmacokinetics in patients. Now, the mechanisms leading to these modulations need to be identified in order to eventually develop strategies to prevent drug toxicity and morbidity in uremic patients.

As complicações biliares mais comuns pós-transplante hepático são as estenoses da anastomose, as estenoses não-anastomóticas e as fístulas biliares e podem ocorrer de diferentes modos, de forma isolada ou associada. A origem do enxerto (doador cadáver ou doador vivo) tem influência na incidência de estenose biliar, bem como na resposta ao tratamento endoscópico. A terapêutica endoscópica utilizando-se esfincterotomia, dilatação balonada da estenose e inserção de próteses biliares através da CPRE é utilizada como método inicial de tratamento dessas complicações. Objetivos: Comparar as diferentes técnicas de tratamento endoscópico das estenoses biliares pós-transplante hepático. Método: Foi realizada uma revisão sistemática da literatura e metanálise sendo a busca conduzida nas bases MEDLINE, EMBASE, Scielo - LILACS e Biblioteca Cochrane até junho de 2015. A metanálise foi executada utilizando-se os softwares Review Manager, 2012 (RevMan) versão 5.2 e OpenMetaAnalyst e os cálculos dos desfechos foram feitos comparando-se os resultados dos estudos incluídos utilizando-se a diferença de risco absoluto e adotando-se um intervalo de confiança (IC) de 95%. Os estudos foram agrupados comparando-se transplantes hepáticos com doador cadáver versus doador vivo; dilatação biliar endoscópica com balão exclusiva versus dilatação biliar endoscópica com balão associada à inserção de próteses plásticas e próteses biliares plásticas comparadas à prótese biliar metálica por endoscopia. Os desfechos clínicos analisados foram incidência da estenose biliar, falha do tratamento endoscópico, resolução da estenose, recorrência da estenose e complicações. Resultados: Foram recuperados 1.110 artigos, sendo motivo de análise dez ensaios clínicos, com apenas um Ensaio Clínico Randomizado e nove Ensaios Clínicos não randomizados, dos quais sete foram incluídos na metanálise. Comparando-se doador cadáver e doador vivo observou-se redução da incidência de estenose biliar (p=0,0001), bem como da falha técnica do tratamento endoscópico (p=0,0009) e da recorrência da estenose biliar (p=0,03) nos transplantes realizados com enxertos provenientes de doador cadáver. Dois estudos compararam o tratamento da estenose da anastomose biliar pós-transplante hepático utilizando dilatação com balão exclusiva versus dilatação com balão associada à inserção próteses plásticas e não foram observadas diferenças estatisticamente significantes em relação aos desfechos falha de tratamento, recorrência da estenose ou complicações. Somente o desfecho clínico complicações teve resultado estatisticamente significante na comparação entre prótese metálica autoexpansível versus prótese plástica no tratamento da estenose da anastomose biliar pós-transplante hepático (p= 0.03). Conclusões: O tratamento da estenose biliar anastomótica pós-transplante hepático com prótese metálica foi igualmente efetivo quando comparado ao uso de prótese plástica, mas associou-se a um menor risco de complicações. A comparação entre dilatação com balão exclusiva e dilatação com balão associada à prótese plástica apresentou resultados semelhantes em relação à falha do tratamento endoscópico, complicações e recorrência da estenose. A utilização de enxerto proveniente de doador cadáver reduziu o risco de estenose biliar pós-transplante hepático e o tratamento endoscópico nesse grupo de pacientes, foi mais efetivo quando comparado com as estenoses biliares após transplante com doador vivo / The most common biliary complications after liver transplantation are anastomotic strictures, non-anastomotic strictures and biliary fistulas and they can occur in different fashions, isolated or in combination. Graft source (cadaveric liver donor or living liver donor) has an influence on the incidence of biliary strictures as well as on the response to endoscopic treatment. The endoscopic treatment using sphincterotomy, balloon dilation and insertion of biliary stents by ERCP (Endoscopic Retrograde Cholangiopancreatography) is used as an initial endoscopic approach to treat these complications. Objectives: To compare different endoscopic techniques to treat post-liver transplantation biliary strictures. Method: It was performed a systematic review of the literature and meta-analysis and the search was carried out on MEDLINE, EMBASE, Scielo-LILACS and Cochrane Library databases until June, 2015. The meta-analysis was made using Review Manager, 2012 (RevMan) version 5.2 and OpenMetaAnalyst software and the calculations of the outcomes were made comparing the results from the included papers by using the difference in absolute risks, adopting a confidence interval of 95%. The studies were grouped comparing cadaveric liver donor versus living liver donor grafts; exclusive balloon dilation versus balloon dilation associated with plastic stents insertion; and plastic stents versus totally covered selfexpandable metal stents. The clinical outcomes were biliary stricture incidence, endoscopic treatment failure, stricture resolution, stricture recurrence and complications. Results: There were retrieved 1,100 articles. Ten clinical trials were analyzed, with just one Randomized Clinical Trial and nine Non-Randomized Clinical Trials, out of which seven were included in the meta-analysis. When comparing cadaveric liver donor transplantation to living liver donor transplantation, it was observed a decrease in the incidence of biliary strictures (p=0.0001), as well as in the technical failure rate of the endoscopic treatment (p=0.0009) and in the biliary stricture recurrence (p=0.03) in the cadaveric liver donor graft group. Two studies have compared the treatment of anastomotic biliary strictures after liver transplantation using balloon dilation exclusive to balloon dilation associated with the insertion of plastic stents, and no statistically significant differences in relation to endoscopic treatment failure, stricture recurrence or complications rates were observed. Only the clinical outcome complications had statistically significant result in a comparison between self-expandable metal stents versus plastic stents in the treatment of post-liver transplantation anastomotic biliary strictures (p=0.03). Conclusions: The treatment of post-liver transplantation anastomotic biliary strictures was equally effective when compared the use of self-expandable metal stents to plastic stents, but the use metallic stents was associated with a lower complication risk. The comparison between exclusive balloon dilation to balloon dilation associated with plastic stents presented similar results in relation to endoscopic treatment failure, complications and stenosis recurrence. The use of graft from cadaveric donor reduced the risk of biliary stenosis after liver transplantation and endoscopic treatment of biliary strictures in these patients were more effective when compared to biliary strictures after living liver donor transplantation

L’insuffisance rénale chronique (IRC) affecte 13 % de la population américaine et son incidence ne cesse d’augmenter. Malgré un ajustement des doses de médicaments administrés en fonction du taux de filtration glomérulaire du patient urémique, près de 40 % des patients reçoivent une dose trop élevée en raison de modifications de l’élimination extrarénale des médicaments chez ces patients. Il est connu que l’IRC affecte l’élimination métabolique des médicaments par les cytochromes P450 et les enzymes de biotransformation de phase II. Nous avons aussi démontré, chez le rat, que l’IRC affecte l’expression et l’activité de transporteurs de médicaments intestinaux entraînant une augmentation de la biodisponibilité de certains médicaments. On retrouve des transporteurs de médicaments dans de nombreux organes comme le foie, les reins et la barrière hématoencéphalique (BHE) où ils jouent des rôles importants dans les éliminations biliaire et rénale et la pénétration des médicaments au cerveau. Le but de ce travail était de mesurer, chez des rats néphrectomisés, les impacts de l’IRC sur l’expression protéique et génique et l’activité des transporteurs de médicaments hépatiques, rénaux et cérébraux. Les transporteurs étudiés sont de la famille des transporteurs ABC (P-glycoprotéine, multidrug-resistance related protein, breast cancer resistance protein) ou des solute carriers (organic anion transporter, organic anion transporting protein). Aussi, une étude réalisée chez l’humain visait à évaluer la pharmacocinétique de deux médicaments : la fexofénadine, un médicament majoritairement transporté, et le midazolam, un substrat du cytochrome P450 3A4, chez des sujets dialysés. Nos résultats montrent que, chez le rat, l’IRC entraîne des modulations de l’expression des transporteurs d’influx et d’efflux hépatiques pouvant entraîner des diminutions du métabolisme hépatique et de l’excrétion biliaire des médicaments. Dans le rein, nous avons démontré des modulations de l’expression des transporteurs de médicaments. Nous avons aussi démontré que l’IRC diminue l’élimination urinaire de la rhodamine 123 et favorise l’accumulation intrarénale de médicaments transportés comme la benzylpénicilline et la digoxine. À la BHE, nous avons démontré des diminutions de l’expression des transporteurs de médicaments. Toutefois, nous n’avons pas observé d’accumulation intracérébrale de trois substrats utilisés (digoxine, doxorubicine et vérapamil) et même une diminution de l’accumulation intracérébrale de la benzylpénicilline. Il semble donc que, malgré les modulations de l’expression des différents transporteurs de médicaments, l’intégrité et la fonction de la BHE soient conservées en IRC. Chez l’humain, nous avons démontré une augmentation de la surface sous la courbe de la fexofénadine chez les sujets dialysés, comparativement aux témoins, suggérant une altération des mécanismes de transport des médicaments chez ces patients. Nous n’avons, toutefois, pas observé de modification de la pharmacocinétique du midazolam chez les patients dialysés, suggérant une activité métabolique normale chez ces patients. Un ou des facteurs s’accumulant dans le sérum des sujets urémiques semblent responsables des modulations de l’expression et de l’activité des transporteurs de médicaments observées chez le rat et l’humain. Ces travaux mettent en évidence une nouvelle problématique chez les sujets urémiques. Nous devons maintenant identifier les mécanismes impliqués afin d’éventuellement développer des stratégies pour prévenir la toxicité et la morbidité chez ces patients. / Chronic renal failure (CRF) affects 13% of the American population and its incidence is rising. Despite dose adjustment of drugs administered to CRF patients according to their glomerular filtration rate, nearly 40% of patients receive up to 6,45-times the recommended dose due to modifications in the extra-renal elimination of drugs. It is known that CRF affects the metabolic elimination of drugs via cytochrome P450s and Phase II biotransformation enzymes. Also, we showed modulations in the expression and activity of intestinal drug transporters in CRF rats that could lead to increases in the bioavailability of drugs. Drug transporters are expressed in various organs including the liver, the kidneys and the blood-brain barrier (BBB) where they play important roles in the biliary and renal elimination, and the brain penetration of drugs. The objective of this work was to measure, using a rat model of CRF, the impacts of CRF on the protein and mRNA expression and the activity of liver, kidney and brain drug transporters. We studied ABC transporters (P-glycoprotein, multidrug-resistance related protein, breast cancer resistance protein) and solute carriers (organic anion transporters, organic anion transporting proteins). Also, a study conducted in human aimed to evaluate the pharmacokinetics of two drugs: fexofenadine, a transported drug, and midazolam, a substrate of cytochrome P450 3A4, in dialyzed patients. In rats, our results show modulations in the expression and activity of hepatic influx and efflux drug transporters that could lead to decreases in the hepatic metabolism and biliary excretion of drugs. In the kidney, we demonstrated modulations in the expression of drug transporters in CRF rats. We also demonstrated that CRF causes a reduction of the urinary elimination of rhodamine 123, a P-glycoprotein substrate, and the intra-renal accumulation of at least two transported drugs: benzylpenicillin and digoxin. Finally, we demonstrated decreases in the expression of influx and efflux drug transporters at the BBB of CRF rats. However, these decreases did not correlate with in vivo changes since BBB permeability of benzylpenicillin was decreased in CRF rats while digoxin, doxorubicin and verapamil permeabilities were unchanged. It thus appears that, even with decreased drug transporters, BBB integrity and function is conserved in CRF. In human, we showed an increase in the area under the curve of fexofenadine in dialyzed subjects compared to healthy controls, suggesting alterations of drug transport mechanisms in these patients. However, we observed no modifications in the pharmacokinetics of midazolam in dialyzed patients, suggesting a normal metabolic activity in these patients. Results from in vitro studies suggest that one or many uremic factors accumulating in the serum of uremic rats and patients are responsible for the observed modulations in drug transporter expression and activity observed in rat and human. This work demonstrates the impacts of CRF on the expression and activity of drug transporters and how they could affect drug pharmacokinetics in patients. Now, the mechanisms leading to these modulations need to be identified in order to eventually develop strategies to prevent drug toxicity and morbidity in uremic patients.